federal_register: 2021-00123

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2021-00123 List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Reopening of the Comment Period Notice The Food and Drug Administration (FDA or the Agency) is reopening the comment period for a notice that appeared in the Federal Register of July 31, 2020, in which FDA identified certain bulk drug substances (active pharmaceutical ingredients) that FDA has considered and proposes to include or not include on the list of bulk drug substances for which there is a clinical need (the 503B Bulks List). The Agency is taking this action in response to a request received during the initial comment period, which asked the Agency to allow interested persons additional time to submit comments. 2021-01-08 2021 1 https://www.federalregister.gov/documents/2021/01/08/2021-00123/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal https://www.govinfo.gov/content/pkg/FR-2021-01-08/pdf/2021-00123.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or the Agency) is reopening the comment period for a notice that appeared in the Federal Register of July 31, 2020, in which FDA identified certain bulk drug substances (active pharmaceutical ingredients) that FDA...  

Links from other tables